CACNB3
Voltage-dependent L-type calcium channel subunit beta-3
As of the edition of 20 October 2026, CACNB3 (voltage-dependent L-type calcium channel subunit beta-3, UniProt P54284) has 1 drug tested at it and 1 company on the list, 0 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P54284
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Where it sits in the cell
- Inside the cell
- Solved structures
- 16
- Disease areas
- Nervous system
- Registered trials of its drugs
- 2
Drugs at this target
| Status | Count |
|---|---|
| Status not established | 1 |
| Total | 1 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| YHD1119 | Status not established | Phase 1 | none listed |
1 of 1 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Undetermined | 1 |
| Total on the list | 1 |